Omeprazole Capsules

Amendment / Modification

This document is Modification P00002 to contract SPE2D2-24-D-0004, dated February 28, 2024. It modifies the contract to include the clause 52.204-30, "Federal Acquisition Supply Chain Security Act Orders-Prohibition (DEC 2023)".

• The entire contract is modified to include the new clause.

• The modification does not extend the hour and date specified for receipt of offers.

• Contractors must acknowledge receipt of this amendment.

• If a contractor desires to change an offer already submitted due to this amendment, the change must be made by electronic communication or letter, referencing the solicitation and amendment number, and received prior to the opening hour and date.

• The modification includes detailed definitions and prohibitions related to "covered articles" and "FASCSA orders".

• Contractors are required to search SAM.gov for applicable FASCSA orders and report any findings that impact their supply chain or use of covered articles/sources.

• Specific reporting requirements and timelines are outlined for contractors who identify new FASCSA orders affecting their performance.

• Contractors must insert the substance of this clause into subcontracts and other contractual instruments.

• If the contractor does not agree to this modification or is not in compliance with the clause, they must immediately notify the Contracting Officer in writing.

Amendment / Modification

• Option #13 is hereby executed for the period February 28, 2025 to February 27, 2026.

• Option #13

• This modification executes an option period for the contract. No changes to proposal deadlines or submission requirements are indicated.

Amendment / Modification

This document is Modification P00001 to contract SPE2D2-24-D-0004, dated February 28, 2024. The modification is effective April 18, 2024.

• The total amount of the contract/order is decreased by $3,522,760.25, changing from $28,836,471.10 to $25,313,710.85.

• The contract value has been adjusted.

• This modification primarily affects the contract's financial value. It is not stated if proposal deadlines or requirements were modified, but the contract value has been reduced.

Solicitation / RFP / RFQ

This document is a contract award (SPE2D2-24-D-0004) for commercial items, specifically Omeprazole capsules in various dosages and quantities. The award is based on Solicitation SPE2D2-23-R-0011 and incorporates the offer from Golden State Medical Supply, Inc. (GSMS).

• The contract covers the supply of Omeprazole 20 MG and 40 MG capsules in bottles of 30, 90, 100, 500, and 1000 counts.

• The contract includes a Base Year and four Option Years.

• The products are manufactured by Laboratories Liconsa (for 20mg) and Towa Pharmaceuticals Europe, S.L. (for 40mg) at facilities in Spain.

• Packaging and final compounding are handled by Golden State Medical Supply, Inc. in Camarillo, CA.

• The total estimated contract value is $28,836,471.10 over 5 years, averaging $5,767,294.22 per year.

• The contract type is an RFP (Request for Proposal).

• The period of performance is not explicitly stated but implied to be 5 years based on the total estimated value.

• This document represents the award, not the initial solicitation for proposals.

• Key deadlines and evaluation criteria are not detailed in this award document.

• The acquisition is set aside for RFP.

• Various FAR and DFARS clauses related to small business concerns, labor standards, and other regulatory requirements are incorporated.

• The quantities specified in the schedule are estimates only.

• The document incorporates numerous Federal Acquisition Regulation (FAR) and Defense Federal Acquisition Regulation Supplement (DFARS) clauses.